scholarly journals Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?

2019 ◽  
Vol 10 (35) ◽  
pp. 8119-8128 ◽  
Author(s):  
Dong Luo ◽  
Xinning Wang ◽  
Sophia Zeng ◽  
Gopalakrishnan Ramamurthy ◽  
Clemens Burda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gold Nanoparticles ◽  
Prostate Specific Membrane Antigen ◽  
Cancer Radiotherapy ◽  
Size Dependent ◽  
High Affinity ◽  
Targeting Peptide ◽  
Prostate Cancer Radiotherapy ◽  
Size Matter ◽  
Specific Membrane

Prostate-Specific Membrane Antigen (PSMA) targeted radiosensitizers are developed for prostate cancer CT imaging and radiotherapy based on gold nanoparticles and a high-affinity targeting peptide, PSMA-1, revealing a size-dependent pattern.

scholarly journals 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

2021 ◽  
Vol 10 (5) ◽  
pp. 205846012110225
Author(s):  
Omer Aras ◽  
Stefan Harmsen ◽  
Richard Ting ◽  
Haluk B Sayman
Keyword(s):  
Prostate Cancer ◽  
Standard Of Care ◽  
Complete Response ◽  
Prostate Specific Membrane Antigen ◽  
Limited Data ◽  
Castrate Resistant Prostate Cancer ◽  
Targeting Peptide ◽  
Castrate Resistant ◽  
Specific Membrane

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.

scholarly journals Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer

ACS Nano ◽  
2018 ◽  
Vol 12 (4) ◽  
pp. 3714-3725 ◽  
Author(s):  
Joey Dacula Mangadlao ◽  
Xinning Wang ◽  
Christopher McCleese ◽  
Maria Escamilla ◽  
Gopalakrishnan Ramamurthy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gold Nanoparticles ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

scholarly journals Proximal seminal vesicle displacement and margins for prostate cancer radiotherapy

2021 ◽  
Author(s):  
Daryl Lim Joon ◽  
Michael Chao ◽  
Angelina Piccolo ◽  
Michal Schneider ◽  
Nigel Anderson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Seminal Vesicle ◽  
Cancer Radiotherapy ◽  
Prostate Cancer Radiotherapy

scholarly journals Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change

2021 ◽  
Vol 27 ◽  
pp. 100331
Author(s):  
Beatrice Detti ◽  
Gianluca Ingrosso ◽  
Carlotta Becherini ◽  
Andrea Lancia ◽  
Emanuela Olmetto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Paradigm Change ◽  
Cancer Radiotherapy ◽  
Prostate Cancer Radiotherapy

Evaluation of set-up errors and estimation of set-up margin during external beam radiation therapy of prostate cancer using electronic portal imaging device (EPID)

2021 ◽  
pp. 1-8
Author(s):  
Daryoush Khoramian ◽  
Soroush Sistani ◽  
Bagher Farhood
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Target Volume ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Cancer Radiotherapy ◽  
Imaging Device ◽  
Portal Images ◽  
Set Up ◽  
Prostate Cancer Radiotherapy

Abstract Aim: In radiation therapy, accurate dose distribution in target volume requires accurate treatment setup. The set-up errors are unwanted and inherent in the treatment process. By achieving these errors, a set-up margin (SM) of clinical target volume (CTV) to planning target volume (PTV) can be determined. In the current study, systematic and random set-up errors that occurred during prostate cancer radiotherapy were measured by an electronic portal imaging device (EPID). The obtained values were used to propose the optimum CTV-to-PTV margin in prostate cancer radiotherapy. Materials and methods: A total of 21 patients with prostate cancer treated with external beam radiation therapy (EBRT) participated in this study. A total of 280 portal images were acquired during 12 months. Gross, population systematic (Σ) and random (σ) errors were obtained based on the portal images in Anterior–Posterior (AP), Medio-Lateral (ML) and Superior–Inferior (SI) directions. The SM of CTV to PTV were then calculated and compared by using the formulas presented by the International Commission on Radiation Units and Measurements (ICRU) 62, Stroom and Heijmen and Van Herk et al. Results: The findings showed that the population systematic errors during prostate cancer radiotherapy in AP, ML and SI directions were 1·40, 1·95 and 1·94 mm, respectively. The population random errors in AP, ML and SI directions were 2·09, 1·85 and 2·29 mm, respectively. The SM of CTV to PTV calculated in accordance with the formula of ICRU 62 in AP, ML and SI directions were 2·51, 2·68 and 3·00 mm, respectively. And according to Stroom and Heijmen, formula were 4·23, 5·19 and 5·48 mm, respectively. And Van Herk et al. formula were 4·96, 6·17 and 6·45 mm, respectively. Findings: The SM of CTV to PTV in all directions, based on the formulas of ICRU 62, Stroom and Heijmen and van Herk et al., were equal to 2·73, 4·98 and 5·86 mm, respectively; these values were obtained by averaging the margins in all directions.

Sign in / Sign up

Export Citation Format

Share Document